Following on from advice received from the company, the timelines for this appraisal are to be confirmed as a pivotal study relevant to this proposed indication has failed to meet its primary endpoint for overall survival. Therefore, NICE has decided to suspend this appraisal from its work programme.
 
Status Suspended
Process STA
ID number 1066

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 August 2017 Suspended, Following on from advice received from the company, the timelines for this appraisal are to be confirmed as a pivotal study relevant to this proposed indication has failed to meet its primary endpoint for overall survival. Therefore, NICE has decided to suspend this appraisal from its work programme.
18 August 2017 As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. Following on from advice received from the company, the timelines for this appraisal are to be confirmed as a pivotal study relevant to this proposed indication has failed to meet its primary endpoint for overall survival. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes
03 July 2017 - 31 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance